Skip to main content

GSK · GSK plc

Track GSK — free
$48.58 -0.66 (-1.34%) At close · Nov 18
Market Cap
$97.38B
Shares
2.00B
Volume · Nov 18 2.2M Avg daily vol (3M) 4.03M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$48.58 Open$49.03 Day$48.55–49.49 52W close$46.11–61.18 Avg vol 30d4.7M Short int16.1M · 0.8% of shares · 3.2d Short vol35% Last earningsOct 28, 2026 DataJan 2020–Nov 2026

Up next

Feb 3, 2027 Scheduled · in 11 wks
call held Oct 28, 2026

Latest documents

2026
Nov 18
Current report 6-K
FDA grants accelerated approval to Nelkarmi for ALK-positive lung cancer

GSK said the FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated advanced ALK-positive non-small cell lung cancer. In the trial, the confirmed overall response rate was 49% (33/67) in patients previously treated with alectinib only.

2 source passages
the US Food and Drug Administration (FDA) has granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received For patients previously treated with alectinib as their only prior ALK TKI, the confirmed overall response rate (ORR) was 49% (33/67; 95% CI: 37%, 62%) Open the document at this passage
Nov 17
Investor event
Restructuring to deliver 1.9 billion of costs by 29

GSK plans to deliver 1.9 billion of costs by 29 through restructuring across its value chain, with most of the savings reinvested in R&D. It also says it will not slow down on BD.

3 source passages
Part of that is taking out or delivering 1.9 billion of costs by 29. Most of that will be reinvested in R&D. And of course, on top of all of that, we're not going to slow down on BD. Open the document at this passage
Nov 17
Current report 6-K
Directors and executives acquire ADS via dividend reinvestment at $50.4500

GSK plc reports that Hal Barron, James Ford and Maya Martinez-Davis acquired American Depositary Shares via dividend reinvestment in executive savings plan accounts on 2026-11-13 at $50.4500.

5 source passages
Acquisition of notional ADS within Dr Barron’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends Acquisition of notional ADS within Mr Ford’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends $50.4500 2026-11-13 Open the document at this passage
Nov 13
Current report 6-K
CHMP supports one-dose Bexsero booster for ages 10+

GSK plc announced CHMP recommended updating the Bexsero label for a single booster dose in individuals aged 10 years and older vaccinated at least two years earlier. Men-B-096 met its primary endpoint, showing immune memory from infant vaccination can be boosted up to 19 years later.

5 source passages
Bexsero (4CMenB) receives positive CHMP opinion for one-dose Meningitis B booster for 10+ year olds GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended updating the Bexsero label to include a single booster dose for individuals aged 10 years and older who were previously vaccinated at least two years earlier with Bexsero. The recommendation is supported by data showing that immune memory established following primary vaccination in infancy can be boosted with a single dose up to 19 years later1. The CHMP’s positive opinion is based on data from Men-B-096, a Phase IIIb open label, multi-centre study which assessed the immune response and safety of a single booster dose of Bexsero in healthy individuals aged 10-20 years who previously completed their primary vaccination series with Bexsero. The study met its primary endpoint. Open the document at this passage
Nov 12
Current report 6-K
Executives and PCA acquired shares under reward plans

GSK plc disclosed that Lynn Baxter and other executives or a PCA acquired ordinary shares under the Share Reward Plan at £19.3453 on 2026-11-10. Maya Martinez-Davis acquired 9.264 notional ADS at $51.5400 on 2026-11-09.

9 source passages
Lynn Baxter Acquisition of Ordinary Shares under the Company’s Share Reward Plan £19.3453 2026-11-10 Maya Martinez-Davis Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account $51.5400 9.264 2026-11-09 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+4.1%
Year over year
Operating margin
24.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
3.8%
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
+2.6%
Trailing year
Short interest
0.8%
Latest settlement · 3.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bearish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −7%
below
Price vs 50-day avg −1%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 16%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −3%
trailing
6-month return −4%
trailing
YTD return −1%
this year
Relative strength 0%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $49 › 200d $52 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +68 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.81% of shares out · ▲ +10.8% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
995 holders — mid 3-yr range
Squeeze score 59
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 26%
annualized · 1-yr
Max drawdown −24%
past year
ATR 2.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Feb 4, 2026
2026
Sales growth 3% – 5%
Core operating profit Non-GAAP 7% – 9%
2026, at closing rates on 28th January
Currency impact on sales -3%
Currency impact on operating profit -6%
Previous outlook earlier release · from the Earnings Call filed Dec 31, 2025

Still-open targets the latest release did not restate under the same label.

Core earnings per share growth · 2026 7% – 9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−7% Bearish
Price vs 50-day avg
−1% Neutral
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
16% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $49 › 200d $52 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +68 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.81% of shares out · ▲ +10.8% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
995 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $46 Now $49 · 16% Range high $61
vs 200-day avg -7% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GSK
GSK plc
this stock
$97.38B -0.9% — — 0.8%
LLY
ELI LILLY & Co
$1.30T +28.7% +44.7% 44.9 0.8%
JNJ
Johnson & Johnson
$656.47B +31.8% +6.0% 41.4 0.7%
ABBV
AbbVie Inc.
$505.56B +25.2% +8.6% 49.2 0.9%
MRK
Merck & Co., Inc.
$339.66B +30.9% +1.3% 142.0 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
995
% held
16.6%
Net QoQ
-14.6M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
164
View
Short & Settlement
Short Interest Rising
Shares short
16.1M
Days to cover
3.2d
Change
+1.6M sh
View
Short Volume
Short vol %
35%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
48.5K
Value
$2.4M
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
48.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$15.0K–$50.0K
Traded
Mar 30, 2026
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 18, 2026
This year
240

GSK said the FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated advanced ALK-positive non-small cell lung cancer. In the trial, the confirmed overall response rate was 49% (33/67) in patients previously treated with alectinib only.

View
Proposed Sales
Value
$2.3M
Shares
44.4K
Filed
Aug 20, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Feb 3, 2027
Last webcast
Nov 17, 2026
View
Investor Relations
Upcoming events
5
View

Performance

5D 20D 120D MTD YTD
GSK -4.0% -2.9% -3.9% -1.9% -0.9%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -0.1% +2.7% -0.4% +1.5% -8.0%

Capital returns

Latest dividend
$0.452 / share · ex Nov 13, 2026
Cut 2%
Paid (TTM)
$1.851 / share · 4 payouts
Dividend yield (TTM, derived)
3.81%
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1131399 CUSIP 37733W204 13F (30d) 922 filings 845 filers Visit website Investor relations